- Home
- IMMP vs AVIR Comparison
IMMP vs AVIR Comparison
Compare IMMP & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- AVIR
- Stock Information
- Founded
- IMMP 1987
- AVIR 2012
- Country
- IMMP Australia
- AVIR United States
- Employees
- IMMP N/A
- AVIR 56
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- IMMP Health Care
- AVIR Health Care
- Exchange
- IMMP Nasdaq
- AVIR Nasdaq
- Market Cap
- IMMP 256.1M
- AVIR 236.7M
- IPO Year
- IMMP N/A
- AVIR 2020
- Fundamental
- Price
- IMMP $1.90
- AVIR $3.04
- Analyst Decision
- IMMP Buy
- AVIR Hold
- Analyst Count
- IMMP 1
- AVIR 1
- Target Price
- IMMP $7.00
- AVIR $6.00
- AVG Volume (30 Days)
- IMMP 128.2K
- AVIR 450.0K
- Earning Date
- IMMP 02-22-2026
- AVIR 11-12-2025
- Dividend Yield
- IMMP N/A
- AVIR N/A
- EPS Growth
- IMMP N/A
- AVIR N/A
- EPS
- IMMP N/A
- AVIR N/A
- Revenue
- IMMP $3,306,742.00
- AVIR N/A
- Revenue This Year
- IMMP N/A
- AVIR N/A
- Revenue Next Year
- IMMP N/A
- AVIR N/A
- P/E Ratio
- IMMP N/A
- AVIR N/A
- Revenue Growth
- IMMP 31.28
- AVIR N/A
- 52 Week Low
- IMMP $1.32
- AVIR $2.46
- 52 Week High
- IMMP $2.71
- AVIR $4.02
- Technical
- Relative Strength Index (RSI)
- IMMP 56.87
- AVIR 45.46
- Support Level
- IMMP $1.68
- AVIR $2.93
- Resistance Level
- IMMP $1.95
- AVIR $3.18
- Average True Range (ATR)
- IMMP 0.09
- AVIR 0.13
- MACD
- IMMP 0.01
- AVIR -0.02
- Stochastic Oscillator
- IMMP 82.14
- AVIR 27.78
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).